Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

325.28 +3.37 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,046,576
Open 322.48
Bid (Size) 323.62 (1)
Ask (Size) 327.89 (1)
Prev. Close 321.91
Today's Range 321.28 - 328.25
52wk Range 260.68 - 346.85
Shares Outstanding N/A
Dividend Yield 2.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors Like Certainty. Trump's Win Gave Them Some.
We're also talking about Super Micro, Nvidia, and weight loss. 
Via The Motley Fool
Topics Government
Exposures Political
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps. 
Via Benzinga

Performance

YTD
+9.38%
+9.38%
1 Month
+0.89%
+0.89%
3 Month
+0.87%
+0.87%
6 Month
+4.88%
+4.88%
1 Year
+23.18%
+23.18%

More News

Read More
3 Healthcare Stocks For Long-Term Growth And Dividends
Via Talk Markets
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
A Closer Look at Amgen's Options Market Dynamics
Via Benzinga
Navigating 14 Analyst Ratings For Amgen
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Amgen (AMGN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
Via Investor's Business Daily
Is Amgen Stock a Buy?
Via The Motley Fool
Looking Into Amgen's Recent Short Interest
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Amgen
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
2 Reliable Dividend Stocks You Can Buy and Hold Forever
Via The Motley Fool
Top Stock Reports For Costco, Coca-Cola & T-Mobile US
Via Talk Markets
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
Via Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.